Invited Speaker Sessions

Tuesday, 23 October

SY01   We Want bNAbs: Passively Infused and Induced by Vaccines

This session will look at state-of-the-art passive infusion designs, including optimal combinations to achieve maximum breadth, coverage, potency and durability. In addition, multiple vaccine concepts designed to induce bNAbs will be presented, from the stage of basic concept up to the clinical trials pipeline. Speakers include:

Zhiwei Chen, The University of Hong Kong AIDS Institute, China
Lynn Morris, National Institute for Communicable Diseases of the NHLS, South Africa
Eloisa Yuste, Instituto de Salud Carlos III, Spain
Kevin Saunders, Duke Human Vaccine Institute, United States
William Schief, The Scripps Research Institute and IAVI, United States

SY02   Early Invaders: Establishment of HIV Infection

This session addresses virus-host interaction at the mucosal border where transmission occurs and where cells involved in early immune responses are both viral targets and defense mechanisms. Speakers include:

Manish Sagar, Boston University, United States
Andrew Harman, The Westmead Institute, University of Sydney, Australia
Eric Arts, University of Western Ontario, Canada
Alexandra Schuetz, MHRP Thailand, Thailand

SY03   Beyond Placebo: Designing and Implementing Next Generation HIV Prevention Trials

This session will explore challenges in designing and conducting the next generation of HIV prevention trials. Topics discussed will include regulatory perspectives, novel trial designs, ethical considerations in provision of standard of prevention, and active community engagement in the design and successful implementation of complex trials in an era of proven HIV prevention tools (including voluntary medical male circumcision and oral PrEP). Speakers include:

Jeffrey Murray, FDA, United States
Deborah Donnell, Fred Hutchinson Cancer Research Center, United States
Paul Ndebele, Medical Research Council of Zimbabwe, Zimbabwe
Luciana Kamel, Fiocruz, Brazil
Gertrude Nanyonjo, UVRI-IAVI HIV Vaccine Program, Uganda

SY04   ARVs for Prevention: Extrapolating from Data to Clinical Practice

Data on mechanisms for PrEP efficacy are somewhat limited, and interpretation varies in creating policy about timing of starting and stopping PrEP for protection. This session will explore the PK, PD and clinical trials, and discuss implications of what is currently known for developing policy on PrEP. Speakers include:

Marta Boffito, Chelsea and Westminster NHS Trust, United Kingdom
Charles Dobard, Centers for Disease Control and Prevention, Division of HIV/AIDS Prevention, United States
Irene Mukui, National AIDS & STI Control Program, Kenya
Emily Bass, AVAC, United States


Wednesday, 24 October

SY05   Close Encounters of the Third Kind: Innate and Adaptive Immune Responses in HIV

This session will review host responses to HIV/SIV infection within mucosal and lymphoid tissues in humans and nonhuman primates. Topics will include the role of molecular pathways implicated in natural immune control, early host response, novel mucosal innate lymphocyte subsets, and relevant findings from acute HIV infection studies.

Anthony Cunningham, The Westmead Institute, The University of Sydney, Australia
Mary Carrington, Frederick National Laboratory for Cancer Research, United States
Zaza Ndhlovu, University of KwaZulu-Natal, South Africa
R. Keith Reeves, Beth Israel Harvard, United States

RT01   Accelerating Product Introduction for Impact

Millions of new HIV infections occur yearly despite availability of novel and effective HIV prevention products. This session will explore best practices for introduction of prevention products, and discuss successes and challenges using lessons learnt from completed demonstration projects. Best practices from sexual and reproductive health technologies and experiences from non-HIV vaccines will be used as examples of implementation planning for product introduction. Speakers include:

Hasina Subedar, Department of Health, South Africa
Alex Coutinho, Partners in Health, Rwanda
Martha Brady, PATH, United States
Swati Gupta, International AIDS Vaccine Initiative, United States
Maria del Rosario Leon, Impacta Salud y Educacion, Peru

SY06   Let's Talk T Cells!

There is an urgent need to revisit approaches to elicit cell-mediated immunity for both vaccine prevention and cure strategies. The session will cover the latest and greatest candidates in pre-clinical and clinical development, as well as address the need to strike the right balance of T cell immunity. Speakers include:

Maximilian Muenchhoff, Pettenkofer-Institute, Germany
Wendy Burgers, Institute of Infectious Disease and Molecular Medicine, UCT, South Africa
Christian Brander, IrsiCaixa, Spain
Tony Kelleher, Kirby Institute, UNSW Sydney, Australia
Rama Amara, Emory University, United States 

SY07   Optimizing PrEP Delivery for PrEP Users

This session will discuss the next phase of PrEP implementation – removing barriers to uptake and persistence of PrEP. The talks will focus on integrating PrEP with family planning. They will include: discussion of MPTs; discussion of new PrEP delivery strategies, such as pharmacy- or telemedicine-based delivery; exploration of “positive frame” methods of describing PrEP to help individuals determine whether they might benefit from PrEP; and discussion of new technologies for increasing uptake and persistence of PrEP. Speakers include:

Renee Heffron, University of Washington, United States
Nneka Nwokolo, Chelsea & Westminster Hospital, United Kingdom
Sarit Golub, Hunter College, United States
Nittaya Phanuphak, Thai Red Cross AIDS Research Centre, Thailand

Thursday, 25 October

SY08   Translating Vaccine Concepts to the Clinic: What We Need to Know

Based on current vaccine concepts, we will do a deep dive into immune mechanisms of protection. Using appropriate animal models, we will evaluate the crosstalk between adaptive and innate immunity, and signatures of protection. Finally, we will examine the role of susceptibility and how to modulate responses. Speakers include:

Michaela Muller-Trutwin, Institut Pasteur, France
Guido Ferrari, Duke University Medical Center, United States
Genoveffa Franchini, National Cancer Institute, United States
Michael Gale, University of Washington, United States
Sudhir Kasturi, Emory University, United States

SY09   Choosing to Use: What People Want from HIV Prevention

HIV prevention products currently in use were introduced after successful clinical trials for efficacy with little consideration of user preference. Results from completed efficacy trials consistently show evidence of low product use among adolescent and young women. This session will explore strategies for adherence support, risk perception, social marketing and end-user engagement strategies during product development. Speakers include:

Jessica Haberer, Massachusetts General Hospital/Harvard Medical School, United States
Ariane van der Straten, RTI International, United States
Wanjiru Mukoma, LVCT Health, Kenya
Ram Prasad, Final Mile, United States

SY10   Mucosal Environment: Barriers and Facilitators of Transmission

This session will review how mucosal environments influence the likelihood that HIV transmission occurs following viral exposure. This includes a review of mucosal factors, such as microbes and host responses that influence sexual transmission, and immunological mechanisms that dictate the integrity of the mucosal barrier and availability of HIV target cells. Speakers include:

Heather Jaspan, University of Cape Town/Seattle Children’s Research Institute, South Africa
Connie Celum, University of Washington, United States
Colleen Kelley, Emory University School of Medicine, United States
Cara Wilson, University of Colorado, United States

RT02   Getting to U: Undetectable = Untransmittable

People living with HIV who are durably virally suppressed are not able to transmit sexually. This roundtable will explore the psychological and behavioral components in deciding to start and stay on treatment, evaluate population impact of viral suppression, explore whether U=U holds for breastfeeding, describe what is known about clinical cohorts of persons being treated and their level of viral suppression, and discuss how to get the word out about U=U within communities. Speakers include:

Robert H. Remien, NY State Psychiatric Institute and Columbia University, United States
Helen Ayles, Zambart/LSHTM, Zambia
Lena Serghides, University Health Network and University of Toronto, Canada
John Brooks, Centers for Disease Control and Prevention, Division of HIV/AIDS Prevention, United States
Bruce Richman, U=U, United States

Conference News


Subscribe to the Newsletter to receive important information about the upcoming Conference.